Interim PK analysis results of a phase IIa, open-label, randomized, pharmacokinetic comparative, cross-over study of melphalan HCl for injection (propylene glycol-free) and alkeran for injection for myeloablative conditioning in multiple myeloma patients undergoing autologous transplantation.

6571 Background: High dose melphalan and autologous transplantation is a standard procedure in transplant eligible multiple myeloma patients. The marketed formulation of melphalan, Alkeran, has marginal solubility and limited chemical stability upon reconstitution. Alkeran uses propylene glycol as a co-solvent, which has been reported to cause some complications. On the other hand, Melphalan HCl for Injection (Propylene Glycol-Free), is a...